Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance

Susana Machado1,2, Andreia Silva1,2, Ana Luísa De Sousa-Coelho1,2

  • 1Centre for Biomedical Research (CBMR), Universidade do Algarve, Campus of Gambelas, Building 8, Room 1.12, 8005-139 Faro, Portugal.

Cancers
|December 15, 2020
PubMed

Insights

Therapy resistance in cancer is a major challenge. This study found that harmine and piperlongumine can overcome resistance mediated by Tribbles homologue 2 (TRIB2) by reactivating FOXO transcription factors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Therapy resistance causes most cancer relapses and hinders clinical outcomes.
  • Tribbles homologue 2 (TRIB2) drives resistance to anti-cancer drugs like dactolisib (BEZ235) by promoting AKT activity and inactivating FOXO transcription factors.

Purpose of the Study:

  • To investigate downstream events of TRIB2 activity.
  • To identify compounds that can reverse TRIB2-mediated drug resistance.

Main Methods:

  • RNA sequencing of isogenic cell lines with varying TRIB2 expression.
  • Connectivity map-based computational analysis to identify drugs reversing TRIB2 expression profiles.
  • Assessing FOXO transcription factor activity and drug synergy.

Main Results:

  • Harmine and piperlongumine reversed TRIB2-associated gene expression profiles.
  • These natural alkaloids synergistically enhanced BEZ235-induced cancer cell toxicity.
  • Harmine and piperlongumine promoted FOXO nuclear translocation and target gene transcription.

Conclusions:

  • The identified computational approach shows potential for drug repurposing.
  • Harmine and piperlongumine may be clinically useful for overcoming TRIB2-mediated therapy resistance in cancer patients.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.3K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.0K
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
792
Phase II Reactions: Miscellaneous Conjugation Reactions01:19

Phase II Reactions: Miscellaneous Conjugation Reactions

Phase II biotransformations are detoxification mechanisms that conjugate xenobiotics with endogenous substances, neutralizing their toxicity.
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
224
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.6K